Meet Vassilis Sboros
A new near-microscopic visualisation approach of the human body that will revolutionise diagnosis of serious diseases.
Our technology aims to address a significant market gap in prostate patient management, with an effective stageing tool. Current need is illustrated by the following facts: 1. 22% of serious prostrate cancer is missed through the current diagnostic pathway. 2. A very large proportion of patients undergo unnecessary operations. There is increasing evidence that prostrate removal is not any more beneficial to patient outcome compared to other treatments. 3. An even larger number of patients undergo biopsy, which also poses significant risks and incurs high costs. 4. Prostate cancer is a disease that concerns a large part of the population so requires diagnostics that are not only hospital based. Specific problems in the current diagnostic pathway include: 5. Recently introduced MRI triaging/stageing is not very sensitive, is expensive, and is required to be done in a separate appointment in a Radiology environment. 6. Current ultrasound guided biopsy has low sensitivity in (<60%) in detecting cancer. 7. Current ultrasound imaging is only provided in grey scale and is inadequate in detecting significant cancer. 8. This all results in repetitive examinations
The Less Grey technology provides a microscopic view of the prostate vascular circulation that is unique to each patient: The resulting super-resolution maps (~50µm) show multi-parametric dynamic information. Our SRI technology: • Enables mapping of abnormal tumour vascular patterns • Uses standard ultrasound equipment in short examination times • Provides information not available through other imaging technology
Our technology may be used as a triaging tool in the prostate patient management pathway, that will help the decision on whether a patient requires biopsy, and/or intervention, as well aid these processing through highly accurate staging.
Less Grey helps visualise otherwise invisible cancers, aiming to reduce mortality and unnecessary treatment, and key opinion leaders (Ahmed – Imperial College) envisage that this has the potential to displace existing technology. The clients will be healthcare providers (eg. NHS UK), hospital consortia (USA).